We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+18.97%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$26.5B
AUM Growth
+$1.52B
Cap. Flow
-$117M
Cap. Flow %
-0.44%
Top 10 Hldgs %
84.24%
Holding
133
New
14
Increased
16
Reduced
60
Closed
7

Top Buys

Rank Stock Value
1
ABCL icon
AbCellera Biologics
ABCL
+$478M
2
NVTA
Invitae Corporation
NVTA
+$181M
3
KOD icon
Kodiak Sciences
KOD
+$170M
4
RARE icon
Ultragenyx Pharmaceutical
RARE
+$52.7M
5
OPT
Opthea Limited American Depositary Shares
OPT
+$41.8M

Top Sells

Rank Stock Value
1
ONC
BeOne Medicines Ltd
ONC
+$450M
2
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$410M
3
EXAS
Exact Sciences
EXAS
+$188M
4
IMMU
Immunomedics Inc
IMMU
+$20.2M
5
AMRN
Amarin Corp
AMRN
+$19.4M

Sector Composition

Rank Sector Weight
1 Healthcare 97.24%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RYTM icon
26
Rhythm Pharmaceuticals
RYTM
$7.31B
$68.8M 0.26%
2,314,873
-156,282
-6% -$3.97M
NBIX icon
27
Neurocrine Biosciences
NBIX
$18.2B
$64.9M 0.24%
676,975
– –
AXSM icon
28
Axsome Therapeutics
AXSM
$11.7B
$63.5M 0.24%
778,834
-180,923
-19% -$13.5M
RARE icon
29
Ultragenyx Pharmaceutical
RARE
$2.46B
$61.5M 0.23%
+444,444
New +$52.7M
NRIX icon
30
Nurix Therapeutics
NRIX
$2.45B
$58.8M 0.22%
1,788,921
– –
BCEL
31
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$57.1M 0.21%
3,532,760
– –
NGNE icon
32
Neurogene
NGNE
$672M
$53.9M 0.2%
191,087
– –
ADAP
33
DELISTED
Adaptimmune Therapeutics
ADAP
$53M 0.2%
9,830,877
+3,500,523
+55% +$19M
APLS
34
DELISTED
Apellis Pharmaceuticals
APLS
$51.3M 0.19%
896,551
– –
KNSA icon
35
Kiniksa Pharmaceuticals
KNSA
$6.23B
$49.5M 0.19%
2,799,577
– –
ADCT icon
36
ADC Therapeutics
ADCT
$140M
$45.4M 0.17%
1,418,107
-269,393
-16% -$8.83M
ALGS icon
37
Aligos Therapeutics
ALGS
$26.3M
$44.5M 0.17%
+64,400
New +$31.4M
HZNP
38
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$43.8M 0.17%
599,110
-67,390
-10% -$5.01M
KRYS icon
39
Krystal Biotech
KRYS
$10.7B
$41.9M 0.16%
698,874
-76,318
-10% -$3.81M
CCXI
40
DELISTED
ChemoCentryx, Inc.
CCXI
$40.7M 0.15%
656,710
-243,111
-27% -$13.9M
GBT
41
DELISTED
Global Blood Therapeutics, Inc.
GBT
$39.9M 0.15%
920,375
– –
DBVT
42
DBV Technologies
DBVT
$813M
$38.3M 0.14%
1,461,426
– –
OPT
43
DELISTED
Opthea Limited American Depositary Shares
OPT
$37.1M 0.14%
+3,308,705
New +$41.8M
MRUS
44
DELISTED
Merus
MRUS
$35.7M 0.13%
2,037,469
– –
ALKS icon
45
Alkermes
ALKS
$8.11B
$30.6M 0.12%
1,535,149
+176,148
+13% +$3.22M
KRRO icon
46
Korro Bio
KRRO
$145M
$30.2M 0.11%
17,130
-1,861
-10% -$2.46M
PTGX icon
47
Protagonist Therapeutics
PTGX
$8.55B
$29M 0.11%
1,436,192
-160,006
-10% -$3.44M
BCAB icon
48
BioAtla
BCAB
$5.34M
$28.1M 0.11%
+16,500
New +$27.6M
RETA
49
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$27.7M 0.1%
223,976
+170,793
+321% +$22.4M
LONA
50
LeonaBio Inc
LONA
$66.1M
$27.6M 0.1%
80,637
-7,598
-9% -$1.79M
1
2
3 4 5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q4 2020 Portfolio in Review

As of Q4 2020, Baker Bros. Advisors held 133 positions worth $26.5B, up 6.1% from $25B the previous quarter. Its ten largest holdings account for 84% of the portfolio.

Baker Bros. Advisors's Q4 2020 filing shows 14 new, 16 increased, 60 reduced and 7 closed positions. Its largest new stake was AbCellera Biologics: 10,450,180 shares worth $421M. The largest sale was BeOne Medicines Ltd, an estimated $450M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 97% a quarter earlier, followed by Financials.

  • Baker Bros. Advisors's largest Q4 2020 buy was AbCellera Biologics: 10,450,180 shares worth $421M.
  • Baker Bros. Advisors added most to Invitae Corporation in Q4 2020, an estimated $181M increase.
  • Baker Bros. Advisors's biggest Q4 2020 reduction was BeOne Medicines Ltd, cutting an estimated $450M.
  • Baker Bros. Advisors fully exited MyoKardia, Inc. Common Stock in Q4 2020, selling an estimated $410M.
  • Baker Bros. Advisors's ten largest holdings make up 84% of its $26.5B portfolio in Q4 2020.
  • Baker Bros. Advisors opened 14 new positions and closed 7 in Q4 2020.
  • Baker Bros. Advisors's portfolio value rose 6.1% quarter-over-quarter to $26.5B.

Based on Baker Bros. Advisors's 13F filing for Q4 2020, filed 16 Feb 2021.